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A Mendelian randomization 
study of the effect of calcium on 
coronary artery disease, myocardial 
infarction and their risk factors
Lin Xu1,2, Shi Lin Lin1 & C. Mary Schooling1,3
Meta-analyses of randomized controlled trials (RCTs) suggest calcium could have adverse effects on 
cardiovascular disease, although these findings are controversial. To clarify, we assessed whether 
people with genetically higher calcium had a higher risk of coronary artery disease (CAD), myocardial 
infarction (MI) and their risk factors. We used a two-sample Mendelian randomization study. We 
identified genetic variants (single nucleotide polymorphisms (SNPs)) that independently contributed to 
serum calcium at genome-wide significance which we applied to large extensively genotyped studies of 
CAD, MI, diabetes, lipids, glycaemic traits and adiposity to obtain unconfounded estimates, with  
body mass index (BMI) as a control outcome. Based on 4 SNPs each 1 mg/dl increase in calcium was 
positively associated with CAD (odds ratio (OR) 1.49, 95% confidence interval (CI) 1.02–2.17), MI  
(OR 1.58, 95% CI 1.06–2.35), LDL-cholesterol (0.21 standard deviations, 95% CI 0.01–0.4), total 
cholesterol (0.21 standard deviations, 95% CI 0.03-0.38) and possibly triglycerides (0.19 standard 
deviations, 95% CI −0.1–0.48), but was unlikely related to BMI although the estimate lacked precision. 
Sensitivity analysis using 13 SNPs showed a higher risk for CAD (OR 1.87, 95% CI 1.14–3.08). Our 
findings, largely consistent with the experimental evidence, suggest higher serum calcium may increase 
the risk of CAD.
Calcium is widely seen as part of a healthy diet that promotes bone health. Recent meta-analysis of randomized 
controlled trials (RCTs) has suggested that calcium has little benefit for fracture prevention1. Unexpectedly, some 
meta-analyses of these RCTs also suggest that calcium may increase the risk of cardiovascular events, myocardial 
infarction (MI) and stroke2–5, although not all meta-analyses of RCTs concur on this point6. Controversy over 
calcium supplements arose with the Auckland Calcium Study (ACS) reporting calcium supplements increased 
cardiovascular disease (CVD) events in a secondary analysis of a large RCT in 20087. However, this was a hypoth-
esis generating study because CVD events were not one of the original study outcomes. Re-analyzing data from 
the US Women’s Health Initiative (WHI), in a sub-group analysis of those not taking calcium supplements at 
randomization, the same authors of the ACS found that calcium supplementation increased the risk of MI2. 
Incorporating the results in a meta-analysis, the use of calcium supplementation increased the risk of MI, by 
21% 2. This meta-analysis only included a small number of trials (n = 7) and compliance was low especially in the 
calcium arm due to adverse effects on gastrointestinal disorders, which might attenuate the potential impact on 
CVD events. Moreover, none of these trials were specifically designed to include primary CVD endpoints, and 
thus CVD events were not collected in a standard and systematic manner. In 2015, another meta-analysis of RCTs 
found the risk of coronary heart disease (CHD) in older women was not increased by calcium supplements6. An 
increase in CVD events in earlier studies was attributed to selection bias6, however, all these studies relied on 
adverse event reporting, whose classification is open to biases, because CVD events may not be considered as 
intervention-related and were not reported in some trials8. Another two recent meta-analysis of RCTs demon-
strated calcium supplements (with or without vitamin D) increased risk of MI by 24–28% 4,9. The discrepancy 
beteen meta-analyses may be due to the inclusion of controversial RCTs, such as trials with participants who 
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differed on CVD risk between study arms at baseline10. Moreover, meta-analysis of RCTs also suggest incon-
sistent effects on cardiovascular disease risk factors, specifically that calcium reduces the risk of type 2 diabetes 
(T2DM)2–5 and improves glucose metabolism but also increases lipids11,12. These contradictory findings for dif-
ferent cardiovascular risk factors again make interpretation uncertain. A large RCT with cardiovascular events as 
the primary endpoint and its risk factors as secondary outcomes would be definitive, but would take several years 
and might be difficult to justify given the lack of convincing evidence for benefits of calcium supplementation, 
even for bone mineral density1.
In this situation assessing coronary artery disease (CAD), MI and their risk factors according to genetically 
determined serum calcium, i.e., Mendelian randomization (MR), may provide insight. Since genetic endowment 
is randomly allocated at conception MR studies provide genetic randomization analogous to the randomiza-
tion in RCTs, and so are less vulnerable to confounding and reverse causation. MR has been successfully used 
in cardiovascular research to investigate potential etiological mechanisms, prioritize drug targets and increase 
understanding of current therapies13. Here, we took advantage of genome wide association studies of calcium and 
large extensively genotyped studies of CAD, MI, T2DM and other CVD risk factors to obtain less confounded 
estimates of the effect of serum calcium on CAD, MI and their risk factors. Given calcium has no effect on body 
mass index (BMI) in meta-analysis of RCTs14,15, we used BMI as a control outcome, because in an unbiased anal-
ysis we would expect to see no association of calcium with BMI.
Methods
Data sources. Serum calcium. From a large meta-analysis of genome wide associations studies (GWAS) 
including 20,611 individuals of European ancestry16, we obtained single nucleotide polymorphisms (SNPs) inde-
pendently contributing to serum calcium at genome wide significance (p < 5 × 10−8). We assessed correlation 
(linkage disequilibrium) between SNPs using SNP Annotation and Proxy (SNAP) Search system (http://www.
broadinstitute.org/mpg/snap/ldsearchpw.php) for the same reference catalog and population17. When the cor-
relation coefficient between SNPs was high (R2 ≥ 0.8) we discarded the SNP with the larger P value, when the 
correlation was lower we kept all SNPs but took into account their correlation matrix. We identified pleiotropic 
effects of these SNPs from Ensembl (Homo sapiens – phenotype) (http://grch37.ensembl.org/Homo_sapiens/
Info/Index), a comprehensive genotype to phenotype cross-reference. We used SNPs that are approximately 
independent as determinants of calcium (i.e., R2 < 0.01) as the main analysis. As a sensitivity analysis we fur-
ther included SNPs with low correlation (0.01 ≤ R2 < 0.8), identified from the linkage disequilibrium correlation 
matrix (Supplementary Table 1).
Coronary artery disease and its risk factors. Association of SNPs with the phenotypes were extracted from 
publicly available consortia. Data on coronary artery disease/myocardial infarction have been contributed by 
Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plusC4D investigators 
and have been downloaded from www.CARDIOGRAMPLUSC4D.ORG18. As no calcium-related SNPs can be 
identified from the CARDIoGRAMplusC4D Metabochip, all summary data on the gene-CAD association were 
obtained from the CARDIoGRAM GWAS, a meta-analysis of 22 GWAS studies of European descent imputed to 
HapMap 2 involving 22,233 cases and 64,762 controls. As sensitivity analysis, we also use CARDIoGRAMplusC4D 
1000 Genomes-based GWAS, a meta-analysis of GWAS studies of mainly European, South Asian, and East Asian, 
descent imputed using the 1000 Genomes phase 1 v3 training set with 38 million variants19. The study interro-
gated 9.4 million variants and involved 60,801 coronary artery disease (CAD) cases and 123,504 controls, and 
43,676 myocardial infarction (MI) cases and 128,199 controls19. Data on T2DM was contributed by the DIAbetes 
Genetics Replication And Meta-analysis (DIAGRAM, http://diagram-consortium.org/downloads.html), 
which includes 12,171 cases and 56,862 controls in Stage 1 GWAS20 and 26,488 cases and 83,964 controls in the 
Trans-ethnic GWAS meta-analysis21,22. Genetic associations with high density lipoprotein (HDL) cholesterol, low 
density lipoprotein (LDL) cholesterol, triglycerides, and total cholesterol in 188,577 people have been contributed 
by Global Lipids Genetics Consortium (GLGC) investigators and have been downloaded from http://csg.sph.
umich.edu/abecasis/public/lipids2013/22. Genetic associations with fasting insulin (n = 38,238), fasting glucose 
(n = 46,186), log-transformed homeostatic model assessment insulin resistance (log-transformed HOMA-IR, 
n = 46,186) have been contributed by Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) 
investigators and have been downloaded from http://www.magicinvestigators.org/, which relates to people of 
European ancestry without diabetes23.
Control outcome. We used BMI as a control outcome that, based on RCTs, should be unrelated to serum 
calcium14,15. Genetic associations with BMI (kg/m2) have been contributed by The Genetic Investigation of 
ANthropometric Traits (GIANT) investigators and have been downloaded from https://www.broadinstitute.
org/collaboration/giant/index.php/GIANT_consortium_data_files which has BMI for 152,893 men and 171,977 
women of European ancestry24.
Statistical analysis. SNP-specific Wald estimates (ratio of SNP on outcome to SNP on calcium) of the effect of 
calcium on each outcome were combined using weighted generalized linear regression to account for correlation 
between the SNPs25, giving an odds ratio (OR) for CAD, MI and T2DM, and regression coefficients (β ) for the 
other outcomes with 95% confidence interval (CI). As a sensitivity analysis we used inverse variance weighted 
(IVW) estimator with fixed effects26. Provided that the genetic variants are uncorrelated, the IVW estimate is 
asymptotically equal to the two-stage least squares estimate commonly used with individual-level data27. In IVW, 
the ratio estimates from each IV (or SNP) are combined in an inverse-variance weighted estimator. We also used 
a weighted median method to combine the SNP specific estimates for the uncorrelated SNPs25. Even after 
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excluding SNPs with known potentially pleiotropic effects (i.e., SNPs that could influence both serum calcium 
and CAD/CVD risk factors), the estimates could still be biased by unknown pathways that directly link the 
genetic determinants of calcium to CAD, MI or other risk factors independent of the pathway via calcium. To 
assess this possible bias, MR-Egger regression was also used28. The same as the IVW method, MR Egger also uses 
an inverse-variance weighted estimator. It differs from the IVW method in that it allows the intercept (pleiotropy 
effect) to be non-zero. If the intercept in the regression model in MR-Egger were truly zero (or were constrained 
to be zero), the MR-Egger slope estimate is the same as the regression coefficient from IVW. If the intercept is zero 
it suggests that there is no violation of the exclusion restriction criteria (i.e., no horizontal pleiotropy); it provides 
an estimate of the average pleiotropic effect across all of the genetic variants, because it reflects the effect of the 
joint instruments on outcome (e.g., CAD/MI) when there is zero effect of the genetic variants on the risk factor 
(e.g. calcium). An intercept term that differs from zero suggests horizontal pleiotropy and that the IVW estimate 
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2 , where R
2 indicates the variance explained by each genetic instrument, K indicated the 
number of instrument, and n indicate the sample size of the first stage29. All statistical analysis was performed 
using STATA 13.1 and R-software (Version 3.2.5).
Results
Genetic determinants of serum calcium. GWAS gave 128 SNPs related to serum calcium with 
p < 1 × 10−5 16,30, from which we excluded 84 SNPs that do not reach genome wide significance (p < 5 × 10−8), 
29 highly correlated SNPs (R2 ≥ 0.8), and 2 SNPs with pleiotropic effects (on bilirubin and parathyroid hormone) 
giving 13 genome-wide significant SNPs (rs4306808 in FAM162A, rs7336933 near DGKH/KIAA0564, rs17711722 
in VKORC1L1, rs1067 in WDR5B; rs17267388 and rs11929034 in PARP9, rs4491840 in CCDC58, rs9864290 in 
CSTA, rs10491003 (closest gene GATA3), and rs16832956, rs17251221, rs13095172 and rs10222633 in CASR) as 
shown in Table 1. For the 13 selected SNPs, 9 were correlated (R2 > 0.1) among each other according to SNAP 
with HapMap release 22, as shown in the correlation matrix in Supplementary Table 1. Of these 13 SNPs, 4 from 
4 different genes (rs7336933 (DGKH/KIAA0564), rs17711722 (VKORC1L1), rs17251221 (CASR) and rs10491003 
(GATA3)) were uncorrelated R2 < 0.05 in HapMap CEU population. The first-stage F-statistics for the IV includ-
ing these 4 SNPs was 52.
Association of genetically determined serum calcium concentrations with CAD risk. Table 2 
shows that the estimates for the causal effect of 1 mg/dl higher serum calcium were consistently in the direction 
of higher risk of CAD and MI based on 4 SNPs, although sometimes the lower limit of the confidence interval 
included the null value in both CARDIoGRAM (OR 1.62, 95% CI 0.86 to 3.07) and CARDIoGRAMplueC4D 
1000 Genomes-based GWAS (OR 1.49, 95% CI 1.02 to 2.17 for CAD, and 1.58, 95% CI 1.06 to 2.35 for MI) 
using IVW or using a weighted median (1.66, 95% CI 1.12 to 1.81 for CAD, and 1.65, 95% CI 1.06 to 2.56 
for MI). The results were consistent based on 13 SNPs in CARDIoGRAM (OR 1.87, 95% CI 1.14 to 3.08) and 
CARDIoGRAMplueC4D 1000 Genomes-based GWAS using IVW (1.25, 95% CI 0.92 to 1.70 for CAD, and 1.32, 
95% CI 0.94 to 1.85 for MI).
Association of genetically determined calcium with CAD risk factors. In all analyses the estimated 
effect of calcium on BMI was null but lacked precision. Similar observations from results using 4 SNPs were 
found for T2DM (OR 1.34, 95% CI 0.65 to 2.74) and glycemic parameters including fasting glucose, insulin and 
log HOMA-IR. In contrast, based on 4 SNPs, the estimates for the causal effect of 1 mg/dl higher serum calcium 
on LDL-cholesterol (0.21 standard deviation, 95% CI 0.01 to 0.40) and total cholesterol (0.29 standard deviation, 
95% CI 0.09 to 0.48) were positive but in sensitivity analysis the confidence interval included the null for triglyc-
erides (0.19 standard deviation, 95% CI − 0.1 to 0.48). Using the MR-Egger method with the 4 SNPs, we could 
SNP Nearest gene Effect allele Other allele Effect† Standard error MAF R2 Main analysis
rs4306808 FAM162A G C 0.054 0.0084 0.1675 0.08
rs7336933 DGKH/KIAA0564 G A 0.022 0.0040 0.1248 0.01 √ 
rs17711722 VKORC1L1 T C 0.021 0.0030 0.4355 0.02 √ 
rs17267388 PARP9 A G 0.036 0.0059 0.1300 0.03
rs1067 WDR5B A G 0.033 0.0059 0.1444 0.03
rs13095172 CSTA;CASR T C 0.028 0.0046 0.3524 0.04
rs11929034 PARP9 A G 0.038 0.0063 0.1312 0.03
rs4491840 CCDC58 A G 0.042 0.0060 0.1673 0.05
rs16832956 CSTA;CASR G C 0.044 0.0053 0.1641 0.05
rs17251221 CASR G A 0.061 0.0063 0.0942 0.06 √ 
rs10222633 CASR G A 0.030 0.0042 0.3852 0.04
rs10491003 GATA3 T C 0.027 0.0050 0.1040 0.01 √ 
rs9864290 CSTA C T 0.028 0.0047 0.4453 0.04
Table 1.  Characteristics of the single nucleotide polymorphisms (SNP) used for genetically determined 
serum calcium. MAF: minor allele frequency. †Increase in calcium (mg/dl) per effect allele.
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not reject the hypothesis that an association of these 4 SNPs with CAD, MI, T2DM or their risk factors was not 
independent of the effects on calcium (Supplementary Table 2).
Discussion
Consistent with most previous meta-analyses of RCTs2–5, we found that higher serum calcium was associated 
with a higher risk of CAD and probably MI, although we cannot definitively rule out the possibility of no effect. 
Findings for CAD risk factors, LDL- and total cholesterol were also positive, consistent with previous RCTs11,12. In 
addition, as expected, calcium appeared not to be associated with BMI14,15. As such, our study replicates findings 
from RCTs and extends them by showing the same pattern of associations for endogenous calcium in very large 
studies including substantial numbers of men as well as of women.
Our findings for CAD are consistent with most previous meta-analyses of RCTs largely pertaining to women2–4,6,9, 
although the estimate is higher than that suggested by these RCTs, which could be because calcium has a stronger 
association with MI in men. However, MR is more suitable for establishing direction than exact effect sizes, 
because genetically determined calcium represents lifetime exposure, whereas the RCTs were relatively short in 
duration and potentially biased towards the null by non-compliance, if the participants were successfully blinded. 
More generally, our findings are consistent with the observation that countries with higher calcium intake, such 
as Northern European countries, also have higher CAD mortality rates, while countries with low calcium intake 
tend to have low CAD mortality, such as China, Korea and Japan31. Of course, ecological evidence never proves 
causality, but this observation does require some explanation.
A previous Mendelian randomization study, using 17 SNPs for calcium from in and around the CASR gene 
region obtained from ~7000 participants in the European Prospective Investigation into Cancer and Nutrition 
(EPIC) -InterAct study, found calcium associated with higher fasting glucose in MAGIC32. However, our estimate, 
with genetically determined calcium obtained from a GWAS with a larger sample (n = 20,611)16, gave no associ-
ation of calcium with fasting glucose (beta = − 0.001, 95% CI − 0.14 to 0.14). We also cannot completely rule out 
the possibility that the result on glucose was due to an insufficient sample size. A post-hoc power calculation for 
specifically glucose assuming a statistical confidence level of 0.05, an effect size of 0.03 (as results from the analysis 
using 13 SNPs), and serum calcium and glucose levels from the GWAS16,23 showed power of less than 20%, sug-
gesting larger MR studies are necessary to further clarify the effect on fasting glucose. Our results are consistent 
with previous RCTs showing calcium supplementation has no effects on fasting glucose, although calcium sup-
plements intake tends to reduce fasting insulin and improve insulin resistance11,12.
The heritability for total calcium is between 33% and 78% in twin studies33,34, suggesting that serum calcium 
levels are tightly regulated. Three major hormones are involved in the regulation of calcium homeostasis, para-
thyroid hormone (PTH), calcitonin and 1,25-dihydroxyvitamin D, which act on their corresponding receptors 
in bone, gut and kidney to maintain serum calcium concentrations35. A key regulator of the PTH release is the 
calcium-sensing receptor (CASR), which is mainly in the plasma membrane of chief cells of the parathyroid 
gland and in cells of the renal tubule36. The CASR gene encodes a protein which binds to calcium and thus 
Main analysis (4 SNPs)
Weighted-median
Sensitivity analysis (13 SNPs)
IVW WGL regression
OR (95% CI) OR (95% CI) OR (95% CI)
CAD (CARDIoGRAM)
CARDIoGRAM GWAS 1.62 (0.86 to 3.07) 1.48 (0.80 to 2.71) 1.87 (1.14 to 3.08)**
1000 Genomes 1.49 (1.02 to 2.17)* 1.66 (1.12 to 1.81)** 1.25 (0.92 to 1.70)
1000 Genomes –MI 1.58 (1.06 to 2.35)* 1.65 (1.06 to 2.56)* 1.32 (0.94 to 1.85)
T2DM
DIAGRAM GWAS 1.34 (0.65 to 2.74) 1.31 (0.62 to 2.8) 1.64 (0.87 to 3.10)
Trans-ethnic GWAS meta-analysis 1.21 (0.71 to 2.07) 1.31 (0.71 to 2.5) 1.06 (0.65 to 1.75)
β (95% CI) β (95% CI) β (95% CI)
BMI, SD (1 SD = 4.77 kg/m2) 0.07 (− 0.1 to 0.25) 0.04 (− 0.12 to 0.2) 0.09 (− 0.04 to 0.22)
LDL-C, SD (1 SD = 38.7 mg/dL) 0.21 (0.01 to 0.40)* 0.20 (− 0.03 to 0.43) 0.15 (− 0.02 to 0.33)
HDL-C, SD (1 SD = 15.5 mg/dL) 0.07 (− 0.11 to 0.25) 0.09 (− 0.11 to 0.3) 0.04 (− 0.12 to 0.21)
TG, SD (1 SD = 90.7 mg/dL) 0.19 (− 0.1 to 0.48) 0.12 (− 0.09 to 0.33) 0.19 (0.03 to 0.35)*
TC, SD (1 SD = 41.8 mg/dL) 0.29 (0.09 to 0.48)* 0.30 (0.08 to 0.51)* 0.21 (0.03 to 0.38)*
Fasting glucose, mmol/l − 0.001(− 0.14 to 0.14) − 0.01(− 0.16 to 0.14) 0.03 (− 0.09 to 0.15)
Fasting insulin, log pmol/l − 0.10 (− 0.33 to 0.13) − 0.04 (− 0.21 to 0.13) − 0.09 (− 0.21 to 0.04)
Log HOMA-IR − 0.09 (− 0.31 to 0.13) − 0.03 (− 0.2 to 0.14) − 0.06 (− 0.20 to 0.07)
Table 2.  Mendelian randomization estimates of the causal association of serum calcium (mg/dl) with 
coronary artery disease (CAD), myocardial infarction (MI) and their risk factors. WGL: weighted 
generalized linear; IVW: inverse variance weighted; SD: standard deviation; OR: odds ratio; CI: confidence 
interval; T2DM: type-2 diabetes mellitus; BMI: body mass index; LDL-C: low-density lipoprotein cholesterol; 
HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol; HOMA-IR: homeostatic 
model assessment of insulin resistance *P < 0.05; **P < 0.01.
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plays an essential role in calcium homeostasis37. Apart from CASR, another gene, GATA3 encodes a GATA tran-
scription factor involved in T cell lymphopoiesis, renal and vestibular morphogenesis, and parathyroid gland 
development38. Functional studies have shown that GATA3 haploinsufficiency causes hypoparathyroidism in 
populations of different ethnicities39–42. Other mechanisms exist by which calcium might contribute to CAD, for 
example by promoting carotid intima-media thickness43, coronary artery calcification, as occurs with calcium 
based phosphate binders versus non-calcium based phosphate binders44, and coagulation45. Acute induction of 
severe hypercalcemia in animal models reduces blood clotting time by 50%46. In vitro, increasing calcium con-
centrations across the physiological range reduces the clotting time of human blood47. These mechanisms could 
underlie effects of calcium on CAD.
Several methodologic considerations and limitations bear discussion. First, the genetic variants used for 
genetically determined calcium were all strongly related to calcium at GWAS level significance. No obvious rea-
son exists for the existence of confounders of the association of these genetic variants with the outcomes consid-
ered here, for example by population stratification, because the underlying studies relate to relatively ethnically 
homogeneous populations of mainly European ancestry. Both calcium levels and CVD rates vary across Europe, 
which could be due to other factors determining calcium and CVD31, of which the calcium related genetic var-
iants are only a marker. However, the estimate was dominated by genetic variants from the calcium-sensing 
receptor (CASR) gene functionally relevant to calcium, making such confounding unlikely. Second, the genetic 
variants used are not known to be associated with other phenotypes that might influence CAD and its risk fac-
tors, thus making biases from direct associations of SNPs with the outcomes, i.e., “pleiotropy” or violation of 
the “exclusion-restriction” assumption, unlikely. Moreover, we found no evidence of directional pleiotropy, i.e. 
that the genetic variants used to predict calcium had effects on CAD or its risk factors independent of effects via 
calcium. Third, we replicated established experimental evidence from meta-analysis of RCTs14,15 by showing that 
calcium had no effect on BMI, which gives more credence to the other estimates using the same genetic deter-
minants of calcium. Fourth, given the use of summarized data in two samples, serum calcium levels were not 
measured in the sample with the outcome. However, two-sample instrumental variable analysis is more robust 
to chance associations than analysis of a single sample48. Fifth, it is not be possible to perform sub-group analysis 
or multivariable analysis as rigorously in two-sample MR as in one-sample MR using individual-level data. For 
example, whether the SNPs for serum calcium have different effects on CAD, T2DM or other CVD risk factors 
at different levels of serum calcium, by sex or at different ages could not be tested, and whether there was sig-
nificant heterogeneity among sub-populations for individual instruments could not be assessed. In addition, 
there might be participant overlap in this two-sample MR (i.e., the same data used both for SNP selection and 
to calculate the IV effect)49. However, given the very large sample size of the CARDIoGRAMplusC4D consor-
tium, assuming a 50% overlapping the sample overlap in this study is only 12%, because the dataset for deriving 
calcium related SNP was much smaller (n = 20,611). Thus bias from sample overlapping, if any, should not be a 
major concern50. Finally, both IVW and MR-Egger methods use weights that under the “NO Measurement Error 
(NOME) assumption”51, that is assuming the SNP-exposure associations to be known, rather than estimated. This 
assumption cannot be tested directly51. However, we used I2 statistics to quantify the strength of NOME violation 
for MR-Egger and did not find significant evidence of the violation.
Our study indicates that genetically higher serum calcium concentrations could have a harmful effect on MI 
and CAD. On the precautionary principle, given calcium does not seem as important in bone health as thought, 
our findings suggest reconsideration of the use of calcium supplementation and particularly fortification in the 
general population, especially in products used by older people who have higher risk of CAD.
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